spacer
home > epc > winter 2017 > global goals
PUBLICATIONS
European Pharmaceutical Contractor

Global Goals

The achievement of the first patient enrolled (FPI) into a clinical trial is one of the most highly anticipated events of the drug/device development process. The pressure to realise this milestone – whether to meet a corporate target or outpace the competition as the baton passes from one trial to the next – is intense and may precipitate premature study starts, resultant delays and an overall decrease in potential revenue. The fleeting elation at the start of enrolment is quickly abandoned. Anxiety regarding the next and arguably more important milestone – last patient out – builds rapidly. In the rush to achieve FPI, thoughtful study design and reasoned start-up considerations are often neglected to the detriment of the overall development timeline. Re-prioritising study design, in addition to careful consideration of multifactorial influences associated with international studies, will facilitate study start-up and help ensure the ratelimiting, last patient out occurs within expected timeframes.

Right the First Time

Due to the intense pressure to achieve FPI, the industry does not often get protocol design right the first time, resulting in a negative impact to overall timelines and cost. 86% of clinical trials are estimated to experience delays, and 94% of clinical trials are delayed by over one month (1). The protracted timelines associated with the clinical development process directly correlate with increased costs and decreased revenues. The projected costs to bring a new drug to market are currently between $161 million and $2 billion (2). For each day a clinical trial is delayed, up to $8 million in revenue is lost. The cost to implement a substantial amendment is approximately $500,000-$1 million, comprised of internal administrative and investigator expenses, contract change orders or new contracts with service providers, additional drug supply and regulatory fees (2). Thus, careful protocol planning is key to preventing design-related delays, which impede last patient out milestones and generate unnecessary costs associated with protocol amendments.

In addition to the complexity of protocol design, studies are increasingly being conducted in multiple countries and regions in an effort to achieve the required patient numbers to address rare diseases or run large outcome trials, which can create complexities that may not have been anticipated when the protocol was originally conceived. Factoring international considerations into trial design may facilitate a more efficient development process and provide earlier access to medicines for patients (3).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Debbie Elliott is Executive Director of clinical operations at Medpace. She has 20 years of clinical research experience, including over four in Phase 1 research and over 16 in Phase 2/3 clinical trials. She holds a PhD in biological psychology with a minor in neurobiology. Most recently, Debbie directed the global study start-up team within Medpace and currently oversees the proposal and feasibilities team.

Colleen Grawe is Senior Regulatory Submissions Manager at Medpace. She has over 18 years of clinical research experience, including 11 years as a Regulatory Submissions Manager facilitating the start-up of clinical trials as well as seven years as a Clinical Research Associate. She has an Associate of Applied Science in radiologic technology and a Bachelor of Arts in journalism.

Jacqueline Moore is Director of Regulatory Submissions at Medpace and has over 20 years of experience in clinical research, primarily in regulatory affairs, covering all phases and a wide variety of therapeutic indications and investigational products. She has a BSc and PhD in pharmacology from the University of Glasgow, UK.

Gina Steidle is Senior Director of strategic proposals and feasibilities at Medpace. She has over 20 years of experience in pharmaceutical research, including clinical trial management, clinical monitoring management and proposals and feasibilities. She has a Bachelor of Science in nursing from Indiana University School of Nursing, US.


spacer
Debbie Elliott
spacer
spacer
spacer
Colleen Grawe
spacer
spacer
spacer
Jaqueline Moore
spacer
spacer
spacer
Gina Steidle
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

£1 Billion Savings Opportunity and Value to the UK Economy from SBRI Healthcare Innovation Programme

An NHS England funded initiative to develop products that address unmet health needs, today released its annual report that shows how the programme has created a pipeline of innovations that could bring the NHS £1 billion of savings.
More info >>

White Papers

Tightening Your Supply Chain Against Counterfeits

World Courier

As today’s global pharmaceutical supply chain grows increasingly longer and more complex, each link provides added opportunity for counterfeiters. While pending regulatory changes promise to tighten the supply chain with respect to production and distribution entities and new packaging technologies will make the identification of counterfeit products easier, the logistics of global distribution remains a weak link. How can the pharmaceutical shipper ensure the security of the supply chain over thousands of miles and extended periods of time when the product is no longer in his possession?
More info >>

 
Industry Events

CPhI India 2017

27-30 November 2017, Bombay Exhibition Centre & MMRDA Grounds, BKC

Connect, network and interact with 1,400+ exhibitors at India's largest and leading pharmaceutical event. CPhI and P-MEC India is the gateway for you to meet the movers and shakers in India’s pharma industry to source high quality pharma solutions at the most competitive prices. Register today for free via: gotocphi.com/india2017
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement